| Jun 5 |
23andMe Launches New Genetic Report on Bipolar Disorder
|
| Jun 4 |
Why 23andMe Stock Tumbled 10% on Tuesday
|
| Jun 4 |
23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
|
| Jun 3 |
23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
|
| May 29 |
Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
|
| May 25 |
23andMe Holding Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
| May 24 |
Q4 2024 23andMe Holding Co. Earnings Call
|
| May 23 |
23andMe Holding Co. (ME) Q4 2024 Earnings Call Transcript
|
| May 23 |
23andMe, citing strategic alternatives review, not providing fiscal 2025 guidance
|
| May 23 |
23andMe GAAP EPS of -$0.43, revenue of $64.03M beats by $2.58M
|
